[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Regional de Alta Especialidad del Bajio\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100538483","raman-spectroscopy-compared-to-flow-cytometry-100538483",false,"NCT06291428","Raman Spectroscopy Compared to Flow Cytometry","Raman Spectroscopy Compared to Flow Cytometry as a Method for Assessing Measurable Residual Disease in Patients With Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Patients diagnosed with ALL for whom MRD determination is clinically necessary will be included in the study.\n\nExclusion Criteria:\n\n* Patients without ALL","ALL","2 Years","70 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","The detection of MRD is associated with an increased risk of relapse and adverse prognosis in all patient groups diagnosed with acute lymphoblastic leukemia (ALL). However, it has a sensitivity level that detects one leukemic cell in 10,000 normal cells, along with other disadvantages such as the need for a panel of fluorescent antibodies for MRD detection, and its measurement is not standardized in many centers. New determination techniques may be necessary for MRD evaluation. Raman spectroscopy is proposed as a potential technique for MRD measurement, which is based on the inelastic scattering of light that occurs when it interacts with matter, causing optical scattering, where a portion of the radiation changes its wavelength (by Raman effect).\n\nObjectives:\n\nMAIN OBJECTIVE:\n\nTo evaluate the presence of MRD in patients with ALL by comparing a standard evaluation method using flow cytometry with a new proposed method using Raman spectroscopy.\n\nSPECIFIC OBJECTIVES:\n\n* To assess the presence of MRD using flow cytometry in patients with ALL.\n* To assess the presence of MRD using Raman spectroscopy in patients with ALL.\n* To perform a comparison between the MRD measurement techniques by determining sensitivity, specificity, positive predictive value, and negative predictive value.\n* To establish the validation of using Raman spectroscopy as a method for MRD evaluation.\n\nStudy Design:\n\nAn observational, cross-sectional, comparative, and diagnostic test study will be conducted on bone marrow aspirate samples from adult and pediatric ALL patients to evaluate the presence of MRD using Raman spectroscopy, comparing the results of this technique with those obtained using flow cytometry. As a diagnostic test study, sensitivity, specificity, positive predictive value, and negative predictive value will be evaluated. The study will be conducted on adult and pediatric patients diagnosed with acute lymphoblastic leukemia treated at the hemato-oncology department of the UMAE No. 1 National Medical Center Bajio and the UMAE Hospital Gynecology-Pediatrics No. 48.\n\nInclusion Criteria:\n\nPatients diagnosed with ALL for whom MRD determination is clinically necessary will be included in the study. Their results will be evaluated using the gold standard, flow cytometry, and compared with results obtained through Raman spectroscopy.",[25],"Acute Lymphoblastic Leukemia","RECRUITING","2025-03-10",{"date":29,"type":30},"2025-03-12","ACTUAL",{"date":32,"type":30},"2024-10-15",{"date":34,"type":21},"2026-12-30",{"name":36,"class":37},"Hospital Regional de Alta Especialidad del Bajio","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":38},"100485006","phase-2-treatment-strategy-for-relapsedrefractory-hodgkin-lymphoma-100485006","NCT05595447","Treatment Strategy for Relapsed\u002FRefractory Hodgkin Lymphoma","Rescue With Brentuximab Plus PD-1 Blockade Followed by Autotransplantation and Consolidation With Brentuximab Plus PD-1 Blockade in Patients With Relapsed\u002FRefractory Hodgkin Lymphoma: Exploratory Single-arm Analysis","Inclusion Criteria:\n\n1. Relapsed\u002Frefractory Hodgkin lymphoma to ABVD with definition of high risk.\n2. Age ≥ 18 years and ≤ 90 years.\n3. Adequate liver function, defined as:\n\n   * Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)\n   * Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN\n   * Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN\n4. Adequate renal functions, defined as:\n\n   • Serum creatinine ≤ 1.5x ULN or glomerular filtration rate \\> 50ml\u002Fmin.\n5. ECOG performance status ≤ 3\n6. Women of reproductive potential should have a serum pregnancy test or negative urine.\n7. Prior signature of the informed consent.\n\nExclusion Criteria:\n\n1. Voluntary withdrawal from the study.\n2. Develop grade 3 or 4 toxicity according to the INH scale.\n3. Loss of follow-up",true,"15 Years","90 Years",{"count":50,"type":21},20,"INTERVENTIONAL",[53,54],"PHASE2","PHASE3","The choice of the best second-line therapy in patients with high LH R\u002FR risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.\n\nWhat is the progression-free survival and rate of metabolic responses complete in patients with high-risk R\u002FR HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade\n\n1?",[57,58,59],"Hodgkin Lymphoma","Refractory Hodgkin Lymphoma","Relapsed Hodgkin's Disease, Adult",[61,62,63],"refractory","relapsed","hodgkin lymphoma",{"date":29,"type":30},{"date":66,"type":30},"2022-10-18",{"date":68,"type":21},"2025-10-18",{"name":36,"class":37},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":38},"100264511","cohort-of-mexican-children-with-diabetes-mellitus-cmc-dm-100264511","NCT02722655","Cohort of Mexican Children With Diabetes Mellitus (CMC-DM)","Characteristics and Evolution of Diabetes Mellitus in Mexican Children: Cohort Study","CMC-DM","Inclusion Criteria:\n\n* Patients with confirmed diagnosis of diabetes mellitus\n\nExclusion Criteria:\n\n\\-","1 Month","17 Years",{"count":81,"type":21},500,"The aim of this study is the identification of complications in diabetes mellitus pediatric patients and to compare the clinical, anthropometric, and biochemical characteristics between children in the different types of diabetes mellitus.",[84],"Diabetes Mellitus",[86],"Pediatrics","2017-08-17",{"date":89,"type":30},"2017-08-22",{"date":91,"type":4},"2008-03",{"date":93,"type":21},"2030-12",{"name":36,"class":37},""]